6-Mercaptopurine (6-MP) Entrapped Stealth Liposomes for Improvement of Leukemic Treatment without Hepatotoxicity and Nephrotoxicity

REFERENCES

• Sharma A., Sharma U. S. Liposomes in drug delivery: progress and limitations. Int J. Pharm 1997; 154: 123–140
   Web of Science ®Google Scholar
• Labana S., Pandey R., Sharma S., Khuller G. K. Chemotherapeutic activity against murine tuberculosis of once weekly administered drugs (isoniazid and rifampicin) encapsulated in liposomes. Int. J. Antimicro. Agents 2002; 20: 301–304
   PubMed Web of Science ®Google Scholar
• Van Hoesel Q., Steerenberg P. A., Crommelin D. J., Vandijk A., Vanoort W., Klein S. Reduced cardiotoxicity and nephrotoxicity with preservation of antitumor-activity of doxorubicin entrapped in stable liposomes in the LOU/M Wsl rats. Cancer Res. 1984; 44: 3698–3705
   PubMed Web of Science ®Google Scholar
• Namba Y., Oku N. Liposomal applications to cancer therapy, Bioact J. Compat. Polym. 1993; 8: 158–177
   Google Scholar
• Janine E., Friedman J. M. Teratogen update: azathioprine and 6-mercaptopurine. Teratology 2002; 65: 240–261
   PubMedGoogle Scholar
• Federico I., Antonello D. P., Barbara L. Clinical and experimental pharmacokinetic interaction between 6-mercaptopurine and methotrexate. Cancer Chemother. Pharmacol. 1996; 37: 409–414
   PubMed Web of Science ®Google Scholar
• Hayder S., Lafolie P., Bjork O., Peterson C. 6-Mercaptopurine plasma levels in children with acute lymphoblastic leukemia: relation to relapse risk and myelotoxicity. Ther. Drug Monit. 1989; 11: 617–622
   PubMed Web of Science ®Google Scholar
• Lafolie P., Hayder S., Bjork O., Ahstrom L., Liliemark J., Peterson C. Large interindividual variations in the pharmacokinetics of oral 6-mercaptopurine in maintenance therapy of children with acute leukemia and non-Hodgkin's lymphoma. Acta. Paediat. Scand. 1986; 75: 797–803
   PubMed Web of Science ®Google Scholar
• Riccardi R., Balis F., Ferrara P., Lasorella A., Poplack D., Mastrangelo R. Influence of food intake on bioavailability of oral 6-mercaptopurine in children with acute lymphoblastic leukemia. Pediatr. Hematol. Oncol. 1986; 3: 319–324
   PubMed Web of Science ®Google Scholar
• Sulh H., Koren G., Whalen C., Soldin S., Zipursky A., Greenberg M. Pharmacokinetic determinations of 6-mercaptopurine myelotoxicity and therapeutic failure in children with acute lymphoblastic leukemia. Clin. Pharmacol. Ther. 1986; 40: 604–609
   PubMed Web of Science ®Google Scholar
• Zimm S., Collins J. M., Riccardi R., O'Neill D., Narang P. K., Chabner B. Variable bioavailability of oral mercaptopurine: is maintenance chemotherapy in acute lymphoblastic leukemia being optimally delivered?. N. Engl. J. Med. 1983; 308: 1005–1009
   PubMed Web of Science ®Google Scholar
• Arulsudar N., Subramanian N., Mishra P., Murthy R. S.R. Preparation, Characterization, and biodistribution study of Technetium-99m-labled leuprolide acetate loaded liposomes in ehrlich ascites tumor bearing mice. AAPS Pharm. Sci. 2004; 6(1)1–12, article 5
   Google Scholar
• Takeuchi H., Kojima H., Yamamoto H., Kawashima Y. Evaluation of circulation profiles of liposomes coated with hydrophilic polymers having different molecular weights in rats. J. Controlled Rel. 2001; 75: 83–91
   PubMed Web of Science ®Google Scholar
• Oku N. Anticancer therapy using glucuronate modified long-circulating liposomes. Adv. Drug Del Rew. 1999; 40: 63–73
   PubMed Web of Science ®Google Scholar
• Herman E. H., Rahman A., Ferrans V. J., Vick J. A., Schein P. S. Prevention of chronic doxorubicin cardiotoxicity in beagles by liposomal encapsulation. Cancer Res. 1983; 43: 5427–732
   PubMed Web of Science ®Google Scholar
• Gabizon A., Catane R., Uziely B. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. 1994; 54: 987–92
   PubMed Web of Science ®Google Scholar
• Newman M. S., Colbern G. T., Working P. K., Engbers C., Amantea M. A. Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long circulating, pegylated liposomes (SPI-077) in tumor-bearing mice. Cancer Chemother. Pharmacol. 1999; 43: 1–7
   PubMed Web of Science ®Google Scholar
• Gondal J. A., Preuss H. G., Swartz R., Rahman A. Comparative pharmacological, toxicological and antitumoral evaluation of free and liposome-encapsulated cisplatin in rodents. Eur. J. Cancer 1993; 29A: 1536–1542
   PubMed Web of Science ®Google Scholar
• Ishida T., Iden D., Allen T. A combinatorial approach to producing sterically stabilized immunoliposomal drugs. FEBS Lett. 1999; 460: 129–133
   PubMed Web of Science ®Google Scholar
• Bangham A. D., Standish M. M., Watkins J. C. Diffusion of univalent ions across the lamellae of swollen phospholipids. J. Mol. Biol. 1965; 13: 238–252
   PubMed Web of Science ®Google Scholar
• Betagiri G. V., Jenkins S. A., Parsons D. L. Stability of Liposomes. Liposomal Drug Delivery Systems, 10th Ed. Technomic Publications, Lancaster 1993; 27–56
   Google Scholar
• Chalmers A. H. A spectrophotometric method for the estimation of urinary azathioprine, 6-mercaptopurine, and 6-thiouric acid. Biochem. Med. 1975; 16(6)513–515
   Google Scholar
• Bhalerao S. S., Harshal A. R. Preparation, optimization, characterization and stability studies of salicylic acid liposomes. Drug Dev. Ind. Pharm. 2003; 29(4)451–467
   PubMed Web of Science ®Google Scholar
• Umrethia M. L., Murthy R. S.R. Optimization of formulation parameters of flutamide liposomes by 33 factorial 26-term logit model. Pharm. Dev. Tech. 2004; 9(4)369–378
   PubMed Web of Science ®Google Scholar
• Gibaldi M., Perrier D. Pharmacokinetics. Marcel Dekker, New York 1982; 409–416
   Google Scholar
• Subramanian N., Murthy R. S.R. Use of electrolyte induced flocculation technique for in-vitro steric stability of sterically stabilized liposomal formulation. Die Pharmazie 2004; 1: 69–74
   Google Scholar
• Sykes E., Woodburn K., Decker D., Kessel D. Effects of cremophor EL on distribution of Taxol to serum lipoproteins. Br. J. Cancer 1994; 70: 401–404
   PubMed Web of Science ®Google Scholar
• Rowinsky E. K., Donehower R. C. Paclitaxel (Taxol). N. Engl. J. Med. 1995; 332: 1004–1014
   PubMed Web of Science ®Google Scholar
• Liebmann J., Cook J. A., Lipschultz C., Teague D., Fischer J., Mitchell J. B. The influence of cremophor EL on the cell cycle effects of paclitaxel in human cell lines. Cancer Chemother. Pharmacol. 1994; 33: 331–339
   PubMed Web of Science ®Google Scholar
• Federico I., Antonello D. P., Barbara L. Clinical and experimental pharmacokinetic interaction between 6-mercaptopurine and methotrexate. Cancer Chemother Pharmacol. 1996; 37: 409–414
   PubMed Web of Science ®Google Scholar
• Zimm S., Collins J. M., O'Neill D., Chabner B. A., Poplack D. G. Inhibition of first-pass metabolism in cancer chemotherapy: interaction of 6-mercaptopurine and allopurinol. Clin. Pharmacol. Ther. 1983; 34: 810–817
   PubMed Web of Science ®Google Scholar
• Lennard L., Keen D., Lilleyman J. S. Oral 6-mercaptopurine in childhood leukemia: parent drug pharmacokinetics and active metabolite concentrations. Clin. Pharmacol. Ther. 1986; 40: 287–292
   PubMed Web of Science ®Google Scholar
• Lennard L., Lilleyman J. S., Van Loon J., Weinshilboum R. M. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukemia. Lancet 1990; 336: 225–229
   PubMed Web of Science ®Google Scholar
• Lennard L., Lilleyman J. S. Variable 6-mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia. J. Clin. Oncol. 1989; 7: 1816–1823
   PubMed Web of Science ®Google Scholar
• Gabizon G., Papahadjopoulos D. Liposomes formulation with prolonged circulation time in blood and enhance uptake by tumors. Pro. Nat. Acad. Sci. USA. 1988; 85: 6949–6953
   PubMed Web of Science ®Google Scholar